Annual Patient-Driven Innovation Summit & Award in Oncology
The Award recognizes Patient Entrepreneurs demonstrating outstanding innovations which advance solutions in the prevention, management or care of cancer
MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, September 17th, 2019: Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, and Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, announced the opening of applications for their third annual Innovation Summit in Cancer. Candidates are invited to submit applications at Lyfebulb-Helsinn 2020 Challenge page, where more information regarding eligibility criteria is available. Submissions may be made until November 17th, 2019.
The Summit is open to Patient Entrepreneurs building groundbreaking companies to advance the prevention, diagnosis, management or care of cancer. Patient Entrepreneurs include cancer patients, cancer survivors, or those having a close relative or loved one with cancer. Applicants for the competition must have established a company with impactful solutions to better manage and improve the quality of life of cancer patients with respect, integrity, and quality.
“While cancer is a broad-reaching disease, the impact of it is felt very personally by each patient and his or her family,” said Karin Hehenberger, MD, PhD, Founder and CEO of Lyfebulb. “We look forward to seeing the latest innovators who have been personally impacted by this disease and turned this experience and the insights gained into much needed solutions for our community.”
The 2020 Lyfebulb-Helsinn Summit will be held at the Grimaldi Forum in Monaco on January 29th and 30th, 2020, culminating in the announcement of the winner of the 2020 Lyfebulb-Helsinn Award of $25,000 on January 30th, during the 14th Monaco Biennale of Oncology. An additional $25,000 Squinto-LePera Award in Oncology will also be awarded at that time.
About the Helsinn Group
Helsinn is a privately-owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.
To learn more about Helsinn Group please visit www.helsinn.com
About Helsinn Investment Fund S.A., SICAR
The Helsinn Investment Fund is focused on investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients.
Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions. For more information, visit www.helsinninvestmentfund.com
About Helsinn International Services sarl
Helsinn International Services sarl is the Helsinn subsidiary which provides a range of advisory services and strategic activities to the Group and its specific companies. In particular, it acts as the advisory company to Helsinn Investment Fund.
Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental illness and migraine.
See www.lyfebulb.com, Facebook, Twitter, Instagram, Lyfebulb LinkedIn, and Karin Hehenberger LinkedIn.
For more information:
Helsinn Group Media Contact
Group Head of Communication
Tel: +41 (0) 91 985 21 21
For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo.
Lyfebulb Media Contact:
Karin Hehenberger, MD, PhD
CEO & Founder, Lyfebulb
Phone: + 1 917-575-0210